Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 124 clinical trials
DNA Sequencing in Clinical Practice, Mayo Clinic Health Tapestry Study

This clinical trial collects information on how sequencing a patient's deoxyribonucleic acid (DNA) (i.e., the genetic material) could impact their health care. This study also develops and improves ways to include genomic information from DNA sequencing into the electronic health record to create a more complete "Health Tapestry" for each …

  • 2 views
  • 23 May, 2022
  • 3 locations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

interleukins
ascites
nervous
absolute neutrophil count
pleural effusion
  • 1032 views
  • 19 Sep, 2022
  • 107 locations
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer (Subito)

Investigator-initiated, international, multicentre, randomized, open-label, (neo)adjuvant phase III study in target population (stage III, HER2-negative, BRCA1-like breast cancer patients

BRCA1
erbb2
immunostimulant
breast adenocarcinoma
HER2
  • 60 views
  • 08 Apr, 2022
  • 10 locations
Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer

This study was designed to assess the safety and efficacy of neoadjuvant therapy with mitomycin C plus cisplatin (MP) in BRCA1-mutated ovarian cancer versus standard regimen (paclitaxel plus

  • 0 views
  • 18 Feb, 2021
  • 1 location
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

triple negative or BRCA1/2 positive (deficient).

cancer
BRCA1
measurable disease
BRCA1/2
brain metastases
  • 5 views
  • 26 Mar, 2022
  • 5 locations
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation (BRCA-P)

This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which, in the

cancer
BRCA1
monoclonal antibodies
breast cancer
breast surgery
  • 4 views
  • 28 Jul, 2022
  • 13 locations
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

This phase II trial studies how well niraparib and dostarlimab work in treating patients with germline or somatic BRCA1/2 and PALB2 mutated pancreatic cancer that has spread to other places in

  • 0 views
  • 25 Jul, 2022
  • 3 locations
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

The aim of this single-arm phase 2 clinical trial is to evaluate the anti-cancer activity of Talazoparib (also known as BMN 673) in patients with advanced breast cancer with specific genetic or tumor genomic alterations. Patients with either triple-negative or HER2-negative breast cancer are eligible.

BRCA1
advanced breast cancer
hysterectomy
serum total bilirubin
gilbert's syndrome
  • 5 views
  • 08 Sep, 2021
  • 1 location
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461, …

  • 2 views
  • 03 Jun, 2022
  • 6 locations
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations

This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2

  • 21 views
  • 15 Sep, 2022
  • 212 locations